Integrated Safety Review of Seven GLP-1 Agonists from Real-World and Trial Data
Background
Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) are highly effective treatments for type 2 diabetes and obesity, but their widespread use necessitates a thorough understanding of their safety profiles. While individual clinical trials provide safety data, a comprehensive, integrated analysis across multiple agents and real-world settings has been lacking. This study aimed to provide an exhaustive pharmacovigilance analysis of seven GLP-1 RAs by combining evidence from global spontaneous reporting databases and pooled clinical trial data.
Results
The analysis identified 23,450 adverse event reports specifically linked to GLP-1 RAs in VigiBase, with gastrointestinal disorders being the most frequently reported category (45% of all reports). Pooled clinical trial data showed nausea in 32% of patients, vomiting in 21%, and diarrhea in 18%, significantly higher than placebo groups (p<0.001 for all). Acute pancreatitis was identified as a rare but serious adverse event, with a pooled incidence of 0.3% across GLP-1 RA clinical trials, representing a 2.5-fold increased risk compared to placebo (p=0.02). Signals for cholelithiasis (gallstones) were also elevated in VigiBase, with a reporting odds ratio (ROR) of 1.8 (95% CI: 1.6-2.0) for GLP-1 RAs compared to other antidiabetic drugs. While thyroid C-cell tumors were a preclinical concern, their incidence in human clinical trials remained very low, with no statistically significant increase observed (p=0.07).
Why It Matters
This study provides a robust, integrated safety profile for widely used GLP-1 RAs, offering a more complete picture than individual studies alone. Understanding these comprehensive safety data is crucial for informing prescribing practices, patient counseling, and risk-benefit assessments, potentially leading to improved patient outcomes. The findings highlight specific adverse events requiring vigilance and underscore the need for continued long-term post-marketing surveillance, especially for rare but serious conditions like pancreatitis and cholelithiasis.